

Specimen Collected: 18-Dec-23 09:32

Autoimmune Vision Loss Panel, Serum | Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:50

Procedure	Result	Units	Reference Interval
CV2 Ab IgG CBA-IFA Screen, Serum	Detected * t1 i1		[<1:100]
Recoverin Ab, IgG by Immunoblot, Serum	High Positive * f1		[Negative]

CV2 Ab IgG Titer by CBA-IFA, Serum | Received: 18-Dec-23 09:40 Report/Verified: 18-Dec-23 09:50

Procedure	Result	Units	Reference Interval
CV2 Ab IgG CBA-IFA Titer, Serum	1:1600 * i2		[<1:100]

**Interpretive Text**

t1: 18-Dec-23 09:32 (CV2 Ab IgG CBA-IFA Screen, Serum)  
CV2 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

**Result Footnote**

f1: Recoverin Ab, IgG by Immunoblot, Serum

INTERPRETIVE INFORMATION: Recoverin Ab, IgG by Immunoblot, Serum

Antibodies to recoverin and CV2/CRMP5 have been associated with paraneoplastic vision loss. Symptoms of vision loss may precede detection of cancer, and a positive test result should prompt a search for malignancy, most often small cell lung adenocarcinoma. A negative test result does not rule out the diagnosis of autoimmune vision loss. Results should be interpreted in the context of the patient's clinical history, neurologic and ophthalmologic exam, and other laboratory findings.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

**Test Information**

i1: CV2 Ab IgG CBA-IFA Screen, Serum

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Screen, Serum

CV2 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2 is associated with small-cell lung cancer and thymoma. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CV2 transfected cell lines for the detection and semiquantification of the CV2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i2: CV2 Ab IgG CBA-IFA Titer, Serum

INTERPRETIVE INFORMATION: CV2 Ab IgG CBA-IFA Titer, Serum

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-352-900106

Report Request ID: 18510380

Printed: 20-Dec-23 13:43

Page 1 of 2

Patient Age/Sex:

Unknown

---

**Test Information**

i2: CV2 Ab IgG CBA-IFA Titer, Serum

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

***Unless otherwise indicated, testing performed at:***

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-352-900106

**Report Request ID:** 18510380

**Printed:** 20-Dec-23 13:43

Page 2 of 2